Development of an

Authors :: Shravan Kumar, Sriraman
Christopher W, Davies
Herman, Gill
James R, Kiefer
Jianping, Yin
Annie, Ogasawara
Alejandra, Urrutia
Vincent, Javinal
Zhonghua, Lin
Dhaya, Seshasayee
Ryan, Abraham
Phil, Haas
Christopher, Koth
Jan, Marik
James T, Koerber
Simon Peter, Williams
Source :: European journal of nuclear medicine and molecular imaging.
Publication Year :: 2022
Abstract: Cancer immunotherapies (CITs) have revolutionized the treatment of certain cancers, but many patients fail to respond or relapse from current therapies, prompting the need for new CIT agents. CD8To this end, we discovered and developed a 13-kDa single-domain antibody (VHH5v2) against human CD8 to enable high-quality, same-day imaging with a reduced radiation burden. To enable sensitive and rapid imaging, we employed a site-specific conjugation strategy to introduce anThe anti-CD8 VHH, VHH5v2, demonstrated binding to a membrane distal epitope of human CD8 with a binding affinity (KOur work reveals the potential of this anti-human CD8 VHH [

Tools